The agreement will primarily focus on providing biological bases for the development of potential Pfizer compounds for autoimmune disease with an initial focus on Lupus, including characterizing mechanisms of action, disease analysis, and drug profiling.
According to the agreement, Pfizer also has the option to engage Nodality in companion diagnostics development.
Nodality executive chairman and interim chief executive officer Michael Goldberg said, "This collaboration, which is Nodality’s second major strategic pharma partnership this year, provides continuing validation of the value the SCNP platform technology can bring to drug development."
The terms of the agreement include an upfront payment, R&D funding, and success-based milestone payments.
Pfizer BioTherapeutics R&D senior vice president Jose-Carlos Gutierrez-Ramos said, "There is a tremendous patient need for new medicines that can impact the pathophysiology of autoimmune diseases."